T
Thomas M.A. Bocan
Researcher at Pfizer
Publications - 48
Citations - 2945
Thomas M.A. Bocan is an academic researcher from Pfizer. The author has contributed to research in topics: Cholesterol & Cholesteryl ester. The author has an hindex of 28, co-authored 48 publications receiving 2842 citations. Previous affiliations of Thomas M.A. Bocan include Parke-Davis.
Papers
More filters
Journal ArticleDOI
Matrix Metalloproteinase Inhibition Attenuates Left Ventricular Remodeling and Dysfunction in a Rat Model of Progressive Heart Failure
J. Thomas Peterson,Hussein Hallak,Linda S B Johnson,Hua Li,Patrick Michael O'brien,Drago Robert Sliskovic,Thomas M.A. Bocan,Mytsi L. Coker,Takuma Etoh,Francis G. Spinale +9 more
TL;DR: MMP activity contributes to LV dilation and progression to LV dysfunction in a rodent HF model, and direct MMP inhibition can attenuate this process.
Journal ArticleDOI
Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties
Sandra M. Sendobry,Joseph A. Cornicelli,Kathryn Welch,Thomas M.A. Bocan,Bradley Dean Tait,Bharat K. Trivedi,Norman L. Colbry,Richard D. Dyer,Steven J. Feinmark,Alan Daugherty +9 more
TL;DR: Results are consistent with a role for 15‐LO in atherogenesis and plasma concentrations achieved in vivo did not inhibit low‐density lipoprotein (LDL) oxidation in vitro.
Journal ArticleDOI
Design and Selection Parameters to Accelerate the Discovery of Novel Central Nervous System Positron Emission Tomography (PET) Ligands and Their Application in the Development of a Novel Phosphodiesterase 2A PET Ligand
Lei Zhang,Anabella Villalobos,Elizabeth Mary Beck,Thomas M.A. Bocan,Thomas Allen Chappie,Laigao Chen,Sarah Grimwood,Steven D. Heck,Christopher John Helal,Xinjun Hou,John M. Humphrey,Jiemin Lu,Marc B. Skaddan,Timothy J. McCarthy,Patrick Robert Verhoest,Travis T. Wager,Kenneth R. Zasadny +16 more
TL;DR: A database consisting of 62 PET ligands that have successfully reached the clinic and 15 radioligands that failed in late-stage development as negative controls was built, which identified a set of preferred parameters for physicochemical properties, brain permeability, and nonspecific binding.
Journal ArticleDOI
Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions. A biochemical, morphological, and morphometric evaluation.
TL;DR: Inhibition of ACAT within the arterial wall by the potent and specific ACAT inhibitor CI-976, even in the absence of plasma cholesterol lowering, can result in the inhibition of atherosclerotic lesion progression and can enhance regression.
Journal ArticleDOI
Rapid on-line determination of cholesterol distribution among plasma lipoproteins after high-performance gel filtration chromatography.
TL;DR: A high-performance gel chromatography (HPGC) system has been developed which allows the unattended on-line determination of lipoprotein cholesterol distribution within 40 min, in microliter quantities of plasma using a single, relatively inexpensive column.